136 related articles for article (PubMed ID: 19145276)
1. Androgen deprivation therapy.
Hoffman P; Djavan B
Rev Urol; 2008; 10(4):305-6. PubMed ID: 19145276
[No Abstract] [Full Text] [Related]
2. Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: A case report.
Wasano K; Sakurai K; Kawasaki T; Kusafuka K; Kasahara M; Kondo N; Inada KI; Ogawa K
Rare Tumors; 2018; 10():2036361318798867. PubMed ID: 30263102
[TBL] [Abstract][Full Text] [Related]
3. Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer.
Fradin J; Kim FJ; Lu-Yao GL; Storozynsky E; Kelly WK
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190244
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and cardiovascular risks of androgen-deprivation therapy for prostate cancer.
Nambudiri VE; Keating NL
Expert Rev Endocrinol Metab; 2010 Jul; 5(4):531-537. PubMed ID: 30780798
[TBL] [Abstract][Full Text] [Related]
5. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
6. Racial Disparities in Diagnosis and Treatment of Depression Associated with Androgen Deprivation Therapy for Prostate Cancer.
Mandel AL; Simhal RK; Shah YB; Wang KR; Lallas CD; Shah MS
Urology; 2024 Apr; 186():75-80. PubMed ID: 38395075
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological profile of COVID-19 in patients with prostate cancer undergoing androgen deprivation therapy at a Brazilian Cancer Center.
Travalini IG; Vergamini LB; Silva ILAFE; Caruso P; Orellana FM; Curado MP; Zequi SC
Einstein (Sao Paulo); 2023; 21():eAO0273. PubMed ID: 37878968
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Intermittent and Continuous Androgen Deprivation Therapy in Prostate Cancer Patients: An Up-to-Date Meta-analysis for Urologists and Medical Providers.
Becker B; Stroever S; Reddy A; de Riese WTW
Urol Pract; 2023 Sep; 10(5):424-434. PubMed ID: 37505912
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
Yoo M; Nelson RE; Haaland B; Dougherty M; Cutshall ZA; Kohli R; Beckstead R; Kohli M
J Natl Cancer Inst; 2023 Nov; 115(11):1374-1382. PubMed ID: 37436697
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Comorbidity and Age on Timing of Androgen Deprivation Therapy in Men with Biochemical Recurrence after Radical Prostatectomy.
Moradzadeh A; Howard LE; Freedland SJ; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen Z; Terris MK; Daskivich TJ
Urol Pract; 2021 Mar; 8(2):238-245. PubMed ID: 37145618
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis.
Chen J; Yuan Y; Fang M; Zhu Y; Sun X; Lou Y; Xin Y; Zhou F
Front Endocrinol (Lausanne); 2022; 13():1074540. PubMed ID: 36733800
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
[TBL] [Abstract][Full Text] [Related]
13. Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
Lee W; Lim B; Kyung YS; Kim CS
Int J Urol; 2022 May; 29(5):414-420. PubMed ID: 35133691
[TBL] [Abstract][Full Text] [Related]
14. Higher serum alkaline phosphatase value indicates the need for bone mineral density testing in non-metastatic prostate cancer patients undergoing androgen deprivation therapy.
Hagiwara K; Sakamoto A; Sasaki K; Kanatani A; Kimura M; Kaneko T; Takahashi S; Yamada Y; Nakagawa T
Jpn J Clin Oncol; 2022 Jan; 52(1):73-80. PubMed ID: 34542155
[TBL] [Abstract][Full Text] [Related]
15. Risk of cardiovascular intervention after androgen deprivation therapy in prostate cancer patients with a prior history of ischemic cardiovascular and cerebrovascular disease: A nationwide population-based cohort study.
Kim DK; Lee HS; Park JY; Kim JW; Hah YS; Ha JS; Kim JH; Cho KS
Urol Oncol; 2022 Jan; 40(1):6.e11-6.e19. PubMed ID: 34315660
[TBL] [Abstract][Full Text] [Related]
16. Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function.
Joyce DD; Wallis CJD; Luckenbaugh AN; Huelster HL; Zhao Z; Hoffman KE; Huang LC; Koyama T; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; Neil BBO; Kaplan SH; Greenfield S; Penson DF; Barocas DA
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):238-247. PubMed ID: 34108648
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529
[TBL] [Abstract][Full Text] [Related]
18. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
19. Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2.
Klein EA; Li J; Milinovich A; Schold JD; Sharifi N; Kattan MW; Jehi L
J Urol; 2021 Feb; 205(2):441-443. PubMed ID: 32897764
[TBL] [Abstract][Full Text] [Related]
20. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
Sari Motlagh R; Quhal F; Mori K; Miura N; Aydh A; Laukhtina E; Pradere B; Karakiewicz PI; Enikeev DV; Deuker M; Shariat SF
J Urol; 2021 Jan; 205(1):60-67. PubMed ID: 32856962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
